Autolus Therapeutics plc - American Depositary Share (AUTL): Price and Financial Metrics
GET POWR RATINGS... FREE!
AUTL POWR Grades
- Sentiment is the dimension where AUTL ranks best; there it ranks ahead of 73.78% of US stocks.
- AUTL's strongest trending metric is Momentum; it's been moving down over the last 52 weeks.
- AUTL's current lowest rank is in the Momentum metric (where it is better than 4.46% of US stocks).
AUTL Stock Summary
- AUTL's price/sales ratio is 97.95; that's higher than the P/S ratio of 96.49% of US stocks.
- As for revenue growth, note that AUTL's revenue has grown 142.36% over the past 12 months; that beats the revenue growth of 95.13% of US companies in our set.
- Autolus Therapeutics plc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -46.75%, greater than the shareholder yield of merely 6% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Autolus Therapeutics plc, a group of peers worth examining would be VBLT, ORGS, XCUR, ACIU, and CBIO.
- Visit AUTL's SEC page to see the company's official filings. To visit the company's web site, go to www.autolus.com.
AUTL Valuation Summary
- AUTL's price/sales ratio is 119.9; this is 956.39% higher than that of the median Healthcare stock.
- Over the past 39 months, AUTL's price/sales ratio has gone down 437.9.
- Over the past 39 months, AUTL's price/sales ratio has gone down 437.9.
Below are key valuation metrics over time for AUTL.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| AUTL | 2021-08-31 | 119.9 | 1.3 | -2.5 | -1.0 |
| AUTL | 2021-08-30 | 119.4 | 1.3 | -2.4 | -1.0 |
| AUTL | 2021-08-27 | 118.5 | 1.3 | -2.4 | -0.9 |
| AUTL | 2021-08-26 | 115.2 | 1.2 | -2.4 | -0.9 |
| AUTL | 2021-08-25 | 114.4 | 1.2 | -2.3 | -0.9 |
| AUTL | 2021-08-24 | 110.0 | 1.2 | -2.2 | -0.8 |
AUTL's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- AUTL has a Quality Grade of D, ranking ahead of 5.33% of graded US stocks.
- AUTL's asset turnover comes in at 0.009 -- ranking 396th of 680 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows AUTL's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.009 | 1 | -1.295 |
| 2021-03-31 | 0.005 | 1 | -1.315 |
| 2020-12-31 | 0.005 | 1 | -1.295 |
| 2020-09-30 | 0.005 | 1 | -1.458 |
| 2020-06-30 | 0.004 | 1 | -1.587 |
| 2020-03-31 | 0.004 | 1 | -1.568 |
AUTL Stock Price Chart Interactive Chart >
AUTL Price/Volume Stats
| Current price | $5.61 | 52-week high | $12.28 |
| Prev. close | $5.58 | 52-week low | $4.60 |
| Day low | $5.57 | Volume | 203,100 |
| Day high | $5.73 | Avg. volume | 1,107,485 |
| 50-day MA | $6.37 | Dividend yield | N/A |
| 200-day MA | $6.52 | Market Cap | 408.09M |
Autolus Therapeutics plc - American Depositary Share (AUTL) Company Bio
Autolus Therapeutics is developing a pipeline of advanced programmable T cell treatment candidates for blood and solid tumor cancers. Autolus‘ T cell therapies target the the blood cancer ALL either through CD19 (in Phase I), or through targeting CD19 and CD22 (Phase I/II). The company's CD19 candidate is claimed "next-generation" due to its fast CD19 dissociation kinetics, which allows to target many CD19+ cells very rapidly. Furthermore, the company’s CAR-T cells target CD269 and TACI to treat multiple myeloma (Phase I/II). An additional candidate undergoing Phase I safety testing targets GD2, a disialoganglioside expressed on tumours of neuroectodermal origin, to treat the rare childhood brain cancer neuroblastoma. The company is based in London, England.
Latest AUTL News From Around the Web
Below are the latest news stories about Autolus Therapeutics plc that investors may wish to consider to help them evaluate AUTL as an investment opportunity.
Autolus Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3LONDON, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2021 financial results and operational highlights before open of U.S. markets on Wednesday, November 3, 2021. Management will host a conference call and webcast at 8:30 am ET/1:30 pm GMT to discuss the company’s financial results and provide a general business up |
Autolus Therapeutics (NASDAQ:AUTL) shareholders have endured a 76% loss from investing in the stock three years agoAs every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like the... |
Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK- Allowing global commercial launch capacity for obe-cel (AUTO1)LONDON, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that planning approval has been granted to build the Company’s new manufacturing facility in Stevenage, UK. The 70,000 square foot facility is being built by Merit Holdings Limited as general contractor for the Reef Group, who will lease |
Autolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of DirectorsLONDON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that John H. Johnson has been appointed as non-executive chairman of its Board of Directors, effective September 15, 2021. Dr. Martin Murphy, who previously served as chairman, will continue to serve as a non-executive Board member. Mr. Johnson brings to Autolus more than 30 years of experience in th |
Autolus Therapeutics to participate in upcoming virtual investor conferences- Goldman Sachs Eleventh Annual Biotech Symposium on September 7- 2021 Virtual Wells Fargo Healthcare Conference on September 10 at 7.30am ET - H.C. Wainwright & Co 23rd Annual Global Investment Conference on September 13, at 7.00am ET LONDON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in three upcoming virtual invest |
AUTL Price Returns
| 1-mo | -10.81% |
| 3-mo | 2.37% |
| 6-mo | -1.58% |
| 1-year | -49.87% |
| 3-year | -80.66% |
| 5-year | N/A |
| YTD | -37.25% |
| 2020 | -32.27% |
| 2019 | -59.81% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...